The main combination trial
A large study called REDEFINE 1 included roughly 3,400 adults without diabetes and lasted 68 weeks. Counting everyone who started, average weight loss was about 20% with CagriSema and about 3% with a dummy shot.
About 9 in 10 people on CagriSema lost at least 5% of their starting weight.
The ingredients did not perform the same
In that trial, average loss was about 11% to 12% with cagrilintide alone, about 15% to 16% with semaglutide alone, and about 20% to 23% with the combination.
Far fewer people received either single ingredient than received the combination. The study was not designed mainly to rank those three results, so the numbers are useful clues rather than a firm ranking.
CagriSema’s average result was lower than the other drug’s
In a direct-comparison trial lasting 84 weeks, average loss was about 20% with CagriSema and about 24% with the other weight-loss drug in the trial, tirzepatide. The company reported these results to investors before a medical journal paper was available. The study did not show that CagriSema came close enough to tirzepatide to count as a similar result.
Important answers are still missing
The trial looking at heart attacks and strokes was still running in September 2026. The public record also did not answer what happens to weight after people stop CagriSema.
Chapter recap
CagriSema has strong weight-loss trial results. That does not make it approved, and those results cannot be assigned to cagrilintide alone.